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Abstract
The risk of several cancers, including colorectal cancer, is increased in patients with obesity and 
type 2 diabetes, conditions characterized by hyperinsulinemia and insulin resistance. Because 
hyperinsulinemia itself is an independent risk factor for cancer development, we examined tissue-
specific insulin action in intestinal tumor formation. In vitro, insulin increased proliferation of 
primary cultures of intestinal tumor epithelial cells from ApcMin/+ mice by over 2-fold. 
Surprisingly, targeted deletion of insulin receptors in intestinal epithelial cells in ApcMin/+ mice 
did not change intestinal tumor number or size distribution on either a low or high-fat diet. We 
therefore asked whether cells in the tumor stroma might explain the association between tumor 
formation and insulin resistance. To this end, we generated ApcMin/+ mice with loss of insulin 
receptors in vascular endothelial cells. Strikingly, these mice had 42% more intestinal tumors than 
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controls, no change in tumor angiogenesis, but increased expression of vascular cell adhesion 
molecule-1 (VCAM-1) in primary culture of tumor endothelial cells. Insulin decreased VCAM-1 
expression and leukocyte adhesion in quiescent tumor endothelial cells with intact insulin 
receptors and partly prevented increases in VCAM-1 and leukocyte adhesion after treatment with 
tumor necrosis factor-α. Knockout of insulin receptors in endothelial cells also increased 
leukocyte adhesion in mesenteric venules and increased the frequency of neutrophils in tumors. 
We conclude that although insulin is mitogenic for intestinal tumor cells in vitro, its action on 
tumor cells in vivo is via signals from the tumor microenvironment. Insulin resistance in tumor 
endothelial cells produces an activated, proinflammatory state that promotes tumorigenesis. 
Improvement of endothelial dysfunction may reduce colorectal cancer risk in patients with obesity 
and type 2 diabetes.
Keywords
hyperinsulinemia; colorectal cancer; adhesion molecules; endothelial cell function
Introduction
Obesity and type 2 diabetes are independent risk factors for the development of colorectal 
cancer and other malignancies [1–3]. Hyperinsulinemia is a central feature of these 
metabolic diseases and is itself an independent risk factor for tumor formation [4], including 
colorectal cancer [5] and colorectal adenomas [6]. Since a mitogenic action of insulin is 
well-described [4, 7–9] it has been proposed that the link between obesity and cancer can be 
explained by a growth-promoting effect of increased insulin action directly on tumor cells 
[4, 10, 11]. However, this hypothesis has not been directly tested in the context of intestinal 
tumor formation.
Chronic inflammation has often been proposed as another possible contributor to the 
relationship between obesity and cancer [12]. Diet-induced obesity changes the immune 
cells resident in the intestine [13] and myeloid cells and T cells can promote tumor growth 
by releasing cytokines like tumor necrosis factor-α (TNF-α) or interleukin-6 or by 
production of reactive oxygen or nitrogen species [14]. We previously found that 
suppression of the proinflammatory factor prostaglandin E2 suppressed the stromal 
inflammatory response and reduced intestinal tumor formation [15]. Anti-inflammatory 
treatment has been effective in clinical translation of such findings as shown by prevention 
of colorectal adenomas with the cyclooxygenase-2 inhibitor celecoxib [16] and reduction of 
colorectal cancer risk with long-term aspirin treatment [17].
Intriguingly, impaired insulin signaling may contribute to the chronic inflammation observed 
in obesity. We previously demonstrated that endothelial-specific deletion of the insulin 
receptor results in a marked increase in the burden of atherosclerosis in the Apoe null mouse 
[18]. Loss of vascular endothelial cell insulin signaling also resulted in a pronounced 
increase in leukocyte rolling and adhesion in the intestinal microcirculation observed during 
in vivo observation of mesenteric venules [18]. This supports a pro-inflammatory effect of 
endothelial cell insulin resistance in the intestine akin to that observed in atherosclerotic 
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plaques. Importantly, endothelial cell insulin resistance occurs early in the development of 
diet-induced obesity in animal models [19, 20] and is present in humans with obesity or type 
2 diabetes [21–24]. Therefore, impaired insulin signaling in endothelial cells could 
contribute to the increased risk of colon cancer in obesity by promoting chronic 
inflammation.
In this study, we examined the contribution of epithelial and endothelial insulin signaling to 
the development of endogenous intestinal tumor formation. Tumor-prone ApcMin/+ mice 
were modified by tissue-specific knockout of the insulin receptor in intestinal epithelium or 
in vascular endothelial cells. Remarkably, tumor burden was not affected by loss of 
epithelial cell insulin signaling in lean animals or in the context of hyperinsulinemia induced 
by high-fat diet feeding. In contrast, loss of the endothelial insulin receptor enhanced 
intestinal tumor formation. Moreover, vascular cell adhesion molecule-1 (VCAM-1), a key 
mediator of vascular inflammation and immune cell recruitment, was upregulated by loss of 
the insulin receptor in primary tumor endothelial cells. We conclude that insulin resistance in 
vascular endothelial cells promotes vascular inflammation and intestinal tumorigenesis.
Results
Insulin has been shown to promote proliferation in a range of cancer cell lines [4, 7–9]. To 
determine whether insulin has this effect in primary tumor cells from mice with the multiple 
intestinal neoplasia (Min) mutation (ApcMin/+ mice), we enzymatically dissociated polyps 
from the small intestine of ApcMin/+ mice and maintained mixed tumor cells in short-term 
culture. Tumor cells were serum-starved and treated with 10 nM insulin for 16 hours, then 
labeled with 5-ethynyl-2′-deoxyuridine (EdU) and analyzed by flow cytometry. An antibody 
against EpCAM, a marker of epithelial cells, stained 70.1± 7.8% of the cell population 
cultured from polyps (Fig. 1). In EpCAM+ tumor epithelial cells, insulin treatment increased 
EdU incorporation by 1.9±0.3 fold, a considerable increase given that treatment with FBS 
increased EdU incorporation by 3.4±0.3 fold (Fig. 1). Therefore, insulin clearly increased 
DNA synthesis in transformed epithelial cells from ApcMin/+ mice during serum-starved 
conditions in culture.
Whole-body glucose tolerance is not altered by Insr knockout in intestinal epithelial cells
Despite the well-known mitogenic effect of insulin on tumor cells it has not been directly 
assessed whether insulin action on normal or transformed epithelial cells contributes to 
intestinal tumor formation in vivo. We therefore generated ApcMin/+ mice with or without 
knockout of the insulin receptor gene (Insr) specifically in intestinal epithelial cells. In these 
Vil1-cre Insrlox/lox ApcMin/+ (VILIRKO-Min) mice, insulin receptor mRNA was reduced by 
97% and 93% in lysate of normal epithelium and intestinal tumors, respectively, compared 
to Insrlox/lox ApcMin/+ controls (Fig. 2A).
VILIRKO-Min and control mice were fed a high-fat or control diet containing 60% or 22% 
of calories provided by fat, respectively. An oral glucose load administered by gavage 
showed that animals with diet-induced obesity had glucose intolerance compared to lean 
animals (Fig. 2B). However, glucose tolerance was not different between VILIRKO-Min and 
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control mice within the same diet group (Fig. 2B). Similarly, plasma insulin was 2.4-fold 
higher in obese versus lean control mice but not different between the genotypes (Fig. 2C).
Loss of insulin signaling in intestinal epithelial cells does not change tumor formation
Surprisingly, loss of insulin signaling in intestinal epithelial cells did not change tumor 
formation in lean animals (Fig. 2D) and tumor size distribution was unchanged (Fig. 2E). 
Consistent with this result, proliferation was similar in tumors from mice of either genotype 
with similar values for the relative frequency tumor cells positive for Ki67 (Fig. 2F and G). 
In addition, the relative frequency of cells positive for cleaved caspase 3, a measure of 
apoptosis, was similar in the two groups (Fig. 2H and I).
Diet-induced obesity and hyperinsulinemia failed to reveal any difference in tumor number 
and size distribution between VILIRKO-Min and control mice (Fig. 2J and K). Again, 
frequency of cells positive for Ki67 or cleaved caspase 3 in tissue sections of tumors was 
similar in VILIRKO-Min and control mice when both groups were fed a high-fat diet (Fig. 
2L and M). Thus, insulin does not affect tumor cell proliferation or apoptosis in these 
intestinal tumors. We therefore concluded that even though insulin increases proliferation of 
adenoma epithelial cells during serum-starved conditions in vitro, insulin action on tumor 
epithelium plays a minor role in vivo where it is only one of many growth factors.
Loss of insulin signaling in vascular endothelial cells does not change systemic glucose 
tolerance
We wondered whether insulin resistance might be more closely related to tumorigenesis than 
hyperinsulinemia and whether tumor stroma could mediate an effect of abnormal insulin 
signaling. We have previously demonstrated that insulin resistance in vascular endothelial 
cells produces an activated endothelium with increased leukocyte adhesion and accelerated 
recruitment of leukocytes to atherosclerotic plaques [18]. We therefore hypothesized that 
endothelial cell insulin resistance can promote tumor progression by facilitating chronic 
inflammation.
We generated ApcMin/+ mice with insulin resistance in vascular endothelial cells by use of 
mice with a cre recombinase transgene under control of the VE-cadherin (Cdh5) promoter 
[25]. To characterize the specificity of cre-mediated recombination we bred mice carrying 
the Cdh5-cre transgene with ApcMin/+ mice and double-fluorescent (mT/mG ) cre reporter 
mice [26]. These reporter mice express a red fluorescent protein (membrane-targeted tandem 
dTomato) in most cells. In cells expressing cre, however, the transgene is recombined and 
expression of dTomato is replaced by a green fluorescent protein (membrane-targeted 
enhanced GFP) [26]. In normal intestine (fig. 3A) and in polyps (fig. 3B), GFP fluorescence 
was clearly confined to vascular structures whereas epithelial cells in villi and polyps had 
uniform red fluorescence (fig. 3A and B). As Cdh5-cre transgene activity was specific for 
our tissues of interest, we then bred Cdh5-cre mice with Insrlox/lox and ApcMin/+ mice to 
generate Cdh5-cre Insrlox/lox mice (EndoIRKO) and their Insrlox/lox controls as well as 
Cdh5-cre Insrlox/lox ApcMin/+ (EndoIRKO-Min) mice and their Insrlox/lox ApcMin/+ controls.
To validate that insulin receptor knockout was restricted to endothelial cells in polyps, we 
used flow-activated cell sorting (FACS) to separate endothelial cells and epithelial cells from 
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enzymatically dissociated tumors and measured insulin receptor expression in the sorted 
cells. Sorting was efficient. Thus, in control animals, mRNA expression of the epithelial cell 
marker Epcam was 14.5±2.1 fold higher in EpCAM+ cells than CD31+ cells (fig. 3C). In 
contrast, Kdr mRNA, another marker for endothelial cells, was 1465±206 fold higher in 
CD31+ cells than EpCAM+ cells (fig. 3D). Epcam and Kdr mRNA was not different 
between EndoIRKO-Min mice and controls in the same category of cell marker (fig. 3C–E). 
Although not a substitute for quantitating number of insulin receptors per cell it is 
interesting that Insr mRNA, normalized to Rplp0 which encodes a ribosomal RNA, was 12.5 
fold higher in CD31+ (endothelial) cells than EpCAM+ (epithelial) cells (fig. 3E). Insr 
mRNA was reduced by 57% in CD31+ cells in EndoIRKO mice but not different in EpCAM
+ cells or double-negative cells (fig. 3E), demonstrating that Cdh5-cre mediated 
recombination had no effect on tumor epithelial cells or, as a group, other tumor cell types.
We then evaluated the efficiency of the targeted gene deletion at the protein level by 
culturing the mixed tumor cell population and isolating primary endothelial cells by 
immunomagnetic selection. We have previously shown that this method yields cultures with 
a very high purity of endothelial cells [18]. In primary tumor endothelial cells cultured from 
control animals with intact Insr, insulin receptor protein was clearly present whereas no 
protein band was detected in cultures from EndoIRKO-Min mice (Fig. 3F). In contrast, 
insulin receptor expression was similar in tumor cells negatively selected by Dynabeads 
conjugated with ICAM-2 antibody (Fig. 3F). Insulin receptor expression was also 
unchanged in bone marrow, peripheral blood leukocytes and spleen from EndoIRKO-Min 
and control mice (Fig. 3F and G). These data show that the insulin receptor was efficiently 
deleted in vascular endothelial cells without signs of reduction in hematopoietic lineages 
where endothelial-specific cre promoters can have off-target activity [18]. In cultured 
primary tumor endothelial cells from control mice with intact insulin receptors, treatment 
with 10 nM insulin increased Akt phosphorylation by 17-fold (fig. 3H and I) and FoxO1 
phosphorylation by 4.7-fold (fig. 3H and J). By contrast, insulin had no significant effect in 
primary tumor endothelial cells from EndoIRKO-Min mice (Fig. 3H–J).
Endothelial cell Insr knockout did not change measures of systemic insulin regulation of 
glucose metabolism. Plasma insulin concentrations were not different in EndoIRKO-Min 
and control mice, 0.60±0.20 and 0.78±0.36 ng/ml, respectively. There was no difference in 
whole-body glucose tolerance (Fig. 3K) or insulin tolerance (Fig. 3L).
Endothelial cell Insr knockout causes increased intestinal tumor formation
At 16 weeks of age, the total tumor number in the small intestine was 42% higher and the 
combined tumor area 60% higher in EndoIRKO-Min than control mice (Fig. 4A–C). There 
were 67.8±14.6 and 47.7±13.8 tumors in EndoIRKO-Min and control mice, respectively 
(Fig. 4B, p=0.002). This difference was manifest without changes in tumor size distribution 
(Fig. 4D), indicating an effect on tumor initiation or early tumor progression. Specifically, 
52±21 and 47±17% of tumors were >1.0 mm in diameter in EndoIRKO-Min and control 
mice, respectively; 8±6 and 7±5% were ≥2.0 mm (both p>0.4).
Loss of insulin signaling in vascular endothelial cells can impair angiogenesis [27]. 
Therefore, endothelial cell Insr knockout, as in EndoIRKO-Min mice, would be expected to 
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decrease tumor angiogenesis and impair tumor growth whereas we in fact found increased 
tumor formation in EndoIRKO-Min mice. Vascular density in tumors measured by CD31 
immunohistochemistry revealed no changes between EndoIRKO-Min and control mice (Fig. 
4E and F). Therefore, although tumor angiogenesis could be limited by endothelial cell Insr 
knockout, such a mechanism is unlikely to affect the phenotype of EndoIRKO-Min mice.
Loss of endothelial cell insulin signaling increases VCAM-1 expression in tumor 
endothelial cells and increases neutrophil recruitment to tumors
Using in vivo microscopy of postcapillary venules in the intestinal mesentery, we have 
previously shown an increase in leukocyte adhesion to endothelial cells in mice with 
knockout of the Insr gene in endothelial cells [18]. The increase in leukocyte adhesion to 
endothelial cells in vivo was completely reversed by a VCAM-1 blocking antibody. We 
therefore hypothesized that a similar mechanism could increase VCAM-1 expression and 
promote chronic inflammation and tumor formation in EndoIRKO-Min mice. In primary 
tumor endothelial cells from EndoIRKO-Min mice, VCAM-1 protein expression was 56% 
higher than in cultures from control mice (Fig. 5A and B). Conversely, in quiescent cultures 
from control mice insulin treatment decreased VCAM-1 expression by 18% (Fig. 5C and D). 
Treatment with TNF-α, on the other hand, induced VCAM-1 expression by 3.8-fold and 10 
nM insulin prevented 56% of this induction (Fig. 5C and D). Therefore, insulin decreases 
VCAM-1 expression in quiescent primary tumor endothelial cells and partly prevents 
VCAM-1 induction when these cells are activated.
In our previous study, Insr knockout in endothelial cells was achieved using a Tie2-cre 
transgene and was complicated by reduction of insulin receptor expression in hematopoietic 
cells [18]. Insr knockout using a Cdh5-cre transgene in the current study is more specific in 
this regard (fig. 3F–G). We therefore characterized leukocyte adhesion in EndoIRKO mice. 
During intravital microscopy, rolling of leukocytes on the endothelium of mesenteric venules 
in EndoIRKO mice was increased by 2.2-fold compared with their controls (fig. 5E–F). This 
result extends the finding of a proinflammatory activation of insulin resistant endothelium to 
the mice generated for the current study.
We then measured the frequency of tumor-associated neutrophils and macrophages. In 
tumors from EndoIRKO-Min mice the frequency of Ly-6G+ cells was 5.6±1.1% compared 
to 3.3±1.6% in control mice (fig. 5G and H, p=0.02). The frequency of F4/80+ cells, 4.3±1.3 
and 3.7±1.3%, respectively, was not different (fig. 5G and I, p>0.4). These data suggest that 
insulin resistant endothelium promotes recruitment of neutrophils to tumors where they may 
promote tumorigenesis.
Discussion
Insulin resistance and ensuing compensatory hyperinsulinemia are central features of obesity 
and type 2 diabetes. Hyperinsulinemia has been implicated in the pathogenesis of a range of 
cancers which are more common in these metabolic diseases [4]. However, in the present 
study we demonstrate that tumor progression is unaffected by hyperinsulinemia via insulin 
action on intestinal epithelial cells. Our data further show that insulin resistance in vascular 
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endothelial cells can promote tumor formation, possibly through mechanisms involving 
chronic inflammation.
In 1924, three years after the discovery of insulin, George Gey published that this hormone 
promotes proliferation of cells in culture [28]. Since then, his suggestion that the observed 
effect could have relevance for malignant growth has been supported by numerous 
publications reporting that insulin increase proliferation of cancer cells in vitro [4, 7, 9, 29–
31]. This has led to the widely held belief that hyperinsulinemia in obesity or type 2 diabetes 
promotes tumor progression by acting directly on tumor cells. We extend these observations 
by showing that insulin increases proliferation of primary adenoma cells in culture. 
However, we find no evidence that the mitogenic action of insulin is relevant to intestinal 
tumor formation in vivo. Indeed, deletion of the insulin receptor in normal intestinal 
epithelium and in tumor cells did not limit tumor formation, proliferation or apoptosis on a 
regular chow diet or in the presence of hyperinsulinemia caused by high-fat feeding. Thus, 
we expect that the role of insulin is minor in the context of a growth factor replete tumor 
microenvironment. An alternative explanation is that hyperinsulinemia may not actually 
result in enhanced insulin signaling in normal or transformed epithelial cells because of 
insulin resistance associated with a high-fat diet. Indeed, impaired insulin signaling has been 
demonstrated in enterocytes from obese individuals [32, 33].
How our finding relates to other cancers associated with obesity or hyperinsulinemia 
remains to be determined. DeRoith and colleagues have implicated insulin in the progression 
of breast cancer using mice expressing a dominant-negative insulin-like growth factor-1 
(IGF-1) receptor in skeletal muscle (MKR mice). These animals have marked 
hyperinsulinemia in the absence of obesity. In mice with breast tumors induced by 
transgenic expression of the polyomavirus middle T oncogene, the MKR mutation causes 
accelerated tumor growth [34]. In addition, enhanced growth of tumors implanted in MKR 
mice was inhibited by insulin receptor knockdown in tumor cells [35]. Therefore, the role of 
insulin action on tumor cells may be different in tumors from different tissues and at 
different stages of malignant transformation.
It is recognized that neutrophils participate in tumor initiation and progression in many 
cancers [36, 37]. In ApcMin/+ mice, depletion of neutrophils by anti- Ly-6G antibody 
reduced tumor formation [38]. It is possible that upregulation of VCAM-1 in insulin 
resistant tumor endothelium changes homing of other immune cells to the tumor 
microenvironment and future studies should further characterize how endothelial cells 
activated by insulin resistance affects interaction with different leukocyte subpopulations. It 
will also be important to provide evidence for causality in this relationship by showing that 
recruitment of neutrophils or other immune cells is responsible for accelerated tumor 
progression in EndoIRKO-Min mice or models of obesity or type 2 diabetes, for example by 
showing that treatment with anti-VCAM-1 antibody inhibits excess tumorigenesis.
To date, vascular biology has made a profound contribution to our understanding of cancer. 
Tumor angiogenesis is now understood as a key driver of tumor progression and 
vasculostatic agents have been employed as successful clinical therapies [39]. In contrast, 
relatively little is known about how endothelial cell recruitment of immune cells contributes 
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to tumorigenesis [40, 41]. Vascular inflammation is present in a number of chronic 
inflammatory diseases [42] and inhibiting immune cell adhesion to the endothelium has 
shown promise as a treatment for inflammatory bowel disease, suggesting that vascular 
inflammation is a primary event in intestinal inflammation [43, 44]. Blocking α4 integrin, 
the VCAM-1 ligand on leukocytes, is efficacious in the treatment of inflammatory bowel 
disease [45] consistent with the notion that endothelial VCAM-1 upregulation due to 
endothelial cell insulin resistance promotes intestinal inflammation. To further understand 
this mechanism it will be important to evaluate whether insulin resistant endothelial cells 
selectively recruit certain immune cell populations and characterize how such recruitment is 
regulated by molecules expressed on or secreted from endothelial cells.
Loss-of-function mutations in the adenomatous polyposis colon (APC) gene cause familial 
adenomatous polyposis. Similar mutations are present in >80% of sporadic colorectal cancer 
and APC mutations are a very frequent if not mandatory event in intestinal tumor formation 
in humans. Loss of Apc in intestinal stem cells is sufficient to initiate tumor formation in 
mice [46] and restoration of Apc leads to sustained regression of intestinal tumors caused by 
loss of Apc [47]. Mice with the multiple intestinal neoplasia (Min) mutation (ApcMin/+ 
mice) therefore are a widely used model of intestinal tumor formation. Removal of 
adenomas can reduce risk of colorectal cancer [48], supporting the notion that in most 
patients, colorectal carcinoma develops from adenoma. The increased tumor formation in 
EndoIRKO mice has relevance for patients with obesity, as this patient group has increased 
for colorectal adenoma [49–51]. However, to test whether endothelial cell insulin resistance 
also affects malignant disease, experiments similar to the ones presented in the current 
manuscript should be performed in animal models of colon adenocarcinoma. Future studies 
should also characterize insulin sensitivity in different types of tumor cells in metabolic 
disease. Impaired insulin signaling is present in intestinal tumors in mice with diet-induced 
obesity, including in ApcMin/+ mice, when measured in tumor lysate [52]. Insulin signaling 
is impaired in large [53] and small [54] vessels in animal models of obesity and in both 
arteriolar [23] and venous endothelial cells [24] in insulin resistant humans. Regardless, it 
will be important to directly demonstrate insulin resistance in intestinal or tumor-associated 
endothelial cells in diet-induced obesity or other models of insulin resistance.
Our findings demonstrate that insulin resistance in endothelial cells, a characteristic of 
endothelial dysfunction in obesity and type 2 diabetes [21–24], can promote tumor 
development. In addition, we find little effect of intestinal epithelial cell insulin signaling on 
intestinal tumorigenesis. These findings provide an impetus to re-examine the dogma of 
insulin as a tumor promoter in obesity and type 2 diabetes and draw attention to the fact that 
important regulatory actions of insulin may be lost in obesity-induced insulin resistance 
[55]. We propose that insulin resistance, not increased insulin stimulation, may drive tumor 
development in certain tissues in these metabolic diseases. Improving endothelial function 
could decrease cancer risk in obesity.
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Materials and Methods
Animals
LIRKO mice [56] were backcrossed >10 times to the C57BL/6 background strain. Insrlox/lox 
mice negative for cre from this colony were cross-bred with ApcMin/+ mice [57] (Jackson 
Labs stock number 002020) and with mice harboring either a cre transgene under control of 
the villin-1 (Vil1) promoter [58] (Jackson Labs stock number 004586) or the VE-cadherin 
(Cdh5) promoter [25] (Jackson Labs stock number 006137). ApcMin/+ mice had been 
backcrossed 95 generations to C57BL/6, Vil1-cre mice at least 6 generations and Cdh5-cre 
at least 13 generations (although a single nucleotide polymorphism panel analysis of Cdh5-
cre at Jackson Labs indicates less extensive backcrossing, see www.jax.org). Cdh5-cre and 
ApcMin/+ mice were also cross-bred with mT/mG mice [26] (Jackson Labs stock number 
007676), backcrossed to the C57BL/6 strain for at least 5 generations.
Mice were fed either a control chow diet with 9.0% fat by weight (22% of calories provided 
by fat, Mouse Diet 9F, LabDiet) or a high-fat rodent diet containing 34.9% fat by weight 
(60% of calories provided by fat, Research Diets cat. no. D12492). Insr knockout animals 
used for experiments were caged with littermate controls from birth to sacrifice. All 
protocols for animal use and euthanasia were reviewed and approved by the Animal Care 
Committee of the Joslin Diabetes Center and were in accordance with NIH guidelines.
Tumor number and size
Animals were sacrificed by CO2 inhalation and perfused with 4% paraformaldehyde in PBS 
(formalin) through the left ventricle. The intestine was flushed with formalin and mesenteric 
fat removed by dissection. The intestine was opened longitudinally and flatmounted in 
formalin under a strip of transparency copy film (Staples) for 30 minutes. The tissue was 
subsequently fixed in formalin for 24 hours at room temperature, then stored at 4 °C in PBS. 
The small intestine was photographed through a stereomicroscope producing overlapping 
images, 15–20 per intestine, which were stitched together (Adobe Photoshop version CS4). 
Circles were drawn to fit tumor outline and the number and size circles were quantified 
automatically (ImageJ version 1.43u). In the images shown in Figure 4, for presentation 
purposes only, the image area representing the intestine was selected in PhotoShop and 
placed on a uniformly black background.
Cell Culture
Primary tumor cells were isolated and cultured using methods described previously [18]. 
Briefly, polyps were removed from a single animal by microdissection, then incubated for 
up to one hour at 37 °C in DMEM containing 500 U/ml collagenase type 1 (Worthington 
Biochemical Corporation), dispase 3 mg/ml Dispase (Roche) and 10% FBS. The tissue 
digest was passed through a 70 μm strainer and centrifuged at 200 × g. Pelleted cells were 
cultured on collagen-coated tissue culture dishes in DMEM with 10% (v/v) FBS. If the 
culture was used for EdU incorporation, the medium was supplemented with 50 ng/ml 
mouse epidermal growth factor (Gold Biotechnology) and used without subculture. If the 
culture was used for isolation of tumor endothelial cells, the medium was instead 
supplemented with 50 μg/ml endothelial cell growth substance (Alfa Aesar) and 100 μg/ml 
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heparin. After Trypsin treatment in the first and second passages cultures were sorted with 
Dynabeads conjugated with sheep anti-rat IgG (Thermo Fisher Scientific) and complexed to 
ICAM-2 rat anti-mouse monoclonal antibody (BD Pharmingen) in DMEM containing 0.1% 
bovine serum albumin (BSA) for 30 minutes at 4 °C. These primary endothelial cells were 
used at passage 2–4. Lung endothelial cells were isolated similarly to tumor endothelial cells 
as described previously [18].
EdU incorporation
Tumor cells were grown to subconfluence, typically for 4 days, then starved in DMEM 
containing 0.1% BSA overnight before treatment with 10 nM insulin or 10% FBS for 16 
hours. Cultures were labeled with 10 μM of 5-ethynyl-2-deoxyuridine (EdU) (Life 
Technologies) for 4 hours. A single-cell suspension was made by trypsin treatment and 
stained by Click-iT EdU Alexa Fluor 647 Kit (Life Technologies) and with an epithelial cell 
adhesion molecule (EpCAM) antibody conjugated to PE (Biolegend). Stained cells were 
analyzed by flow cytometry using an LSRII instrument (BD Biosciences).
Intravital microscopy of leukocyte-endothelial cell interaction
Animals were anaesthetized by intraperitoneal injection of avertin 480 mg/kg, supplemented 
as necessary. Circulating leukocytes were fluorescently labeled by intravenous injection of 
0.3 mg/kg rhodamine 6G (Sigma-Aldrich). The abdomen was opened in the midline, a loop 
of ileum exteriorized and the mouse placed on a heated stage (Harvard Apparatus WP-10). 
Second- or third-order mesenteric venules were observed by fluorescence microscopy using 
an Axio Observer D1 microscope with inverted configuration and a 20× objective, resulting 
in a final magnification of 200×. Images were acquired at 60 frames per second at high 
resolution by a digital video camera (Hamamatsu C11440-22CU CMOS Camera) and Zeiss 
software (ZEN Pro 2012). Rolling leukocytes was measured as the total number of 
leukocytes crossing a 100 μm venular segment in 60 seconds at a velocity significantly lower 
than the centerline velocity.
Flow cytometry and fluorescence-activated cell sorting (FACS) of dissociated tumor cells
Intestinal tumors were isolated by dissection under a stereomicroscope, minced by scalpels 
and digested for one hour in DMEM containing 2 mg/ml (560 U/ml) collagenase I 
(Worthington) and 3 mg/ml Dispase (Roche). Cell suspensions were washed and passed 
through a 40 μm filter and Fc receptors were blocked using TruStain fcX (anti-mouse 
CD16/32) antibody (Biolegend cat. no. 101320), then stained with EpCAM antibody 
conjugated to Brilliant Violet 421 (BioLegend cat. no. 118225), F4/80 antibody conjugated 
to Alexa Fluor 488 (BioLegend cat. no. 123119), and Ly-6G antibody conjugated to APC-
Cy7 (BioLegend cat. no. 127623). Dead cells were stained with propidium iodide (PI) 
immediately before analysis. Filtered cells were stained with antibodies and sorted on a 
Moflo Legacy (Cytomation, currently Beckman Coulter) or analyzed on an LSRII 
instrument (BD Biosciences). For FACS, 100 000–300 000 cells were sorted directly into 
TRI Reagent (Molecular Research Center). For all analysis, populations were first gated for 
cells (as opposed to debris) in a FSC-A vs. SSC-A graph, for single cells (as opposed to 
doublets/aggregates) in a FSC-A vs. FSC-W graph and for live (PI-negative) cells. 
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Compensation was performed using single-stained cells and gating was aided by 
fluorescence minus one (FMO) controls.
Other analyses
Real-time PCR, Western blotting, glucose and insulin tolerance tests, insulin ELISA and 
immunostaining were performed as described previously [18].
Statistical analysis
Comparisons were made using paired t test for the cell culture studies and unpaired t test 
when comparing variables in mice with p < 0.05 considered statistically significant. In text 
and graphs, data are presented as the mean ± standard deviation.
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Figure 1. Insulin increases proliferation of serum-starved primary polyp epithelial cells in 
culture
Polyps were isolated from ApcMin/+ mice and tumor cells dissociated by enzymatic 
digestion were grown in culture. Cells were serum-starved overnight, then stimulated with 
insulin for 16 hours. In the final 4 hours of this period, cultures were labeled with EdU. The 
proportion of cells double-positive for EpCAM, an epithelial cell marker, and EdU were 
analyzed by flow cytometry. Scatter plots show representative data from flow cytometry. The 
graph shows mean values from independent experiments using primary culture from 4 
different animals. *, p<0.05.
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Figure 2. Loss of the insulin receptor in intestinal epithelial cells does not change tumorigenesis
ApcMin/+ mice with insulin receptor knockout targeted to intestinal epithelial cells were 
studied (genotype Vil1-cre Insrlox/lox ApcMin/+, abbreviated VILIRKO-Min and labeled “V” 
in this figure). They were compared to littermate controls (genotype Insrlox/lox ApcMin/+ and 
labeled “c” in this figure). A. Insr mRNA was measured by real-time PCR in lysate of 
tumors or normal jejunum. B. Mice were fed a low-fat or high-fat diet for 8 weeks and 
subjected to an oral glucose tolerance test at 12 weeks of age. For the test, mice fasted 
overnight and were given 2 mg glucose per g body weight by gavage. Glucose concentration 
was measured in plasma from tail blood. C. Insulin was measured in plasma in fasted 
animals. D. Tumor number was counted in the entire small intestine of 9 control mice and 11 
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VILIRKO-Min mice fed a low-fat diet. E. Tumor number in 3 categories of tumor size. F. 
Representative microphotos of Ki67 (green) and E-cadherin (red) immunohistofluorescence 
performed on sections of paraffin-embedded tissue. Scale bars represent 50 μm. G. 
Frequency of Ki67+ cells in tumor tissue. H. Representative microphotos of cleaved 
caspase-3 (CC3) immunohistofluorescence (green) and DAPI (blue). Scale bars represent 50 
μm. I. Frequency of CC3+ cells in tumor tissue. J. Tumor number in the entire small 
intestine of 9 control mice and 11 VILIRKO-Min mice fed a high-fat diet. K. Size 
distribution of small intestinal tumors in mice fed a high-fat diet. L. Frequency of Ki67+ 
cells in tumor tissue mice fed a high-fat diet. M. Frequency of CC3+ cells in tumor tissue in 
mice mice fed a high-fat diet. All panels: *, p<0.05.
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Figure 3. Characterization of EndoIRKO-Min mice
A–B. Cdh5-cre ApcMin/+ mice were crossed with mT/mG mice, a double-fluorescent 
reporter of cre recombinase activity. Offspring have ubiquitous expression of a red 
fluorescent protein, i. e. membrane-targeted tandem dTomato (dTomato), except in cells with 
cre-mediated recombination of the mT/mG transgene where dTomato expression is replaced 
with expression of membrane-targeted enhanced green fluorescent protein (GFP). 80 μm 
cryosections of formalin-fixed tissue was stained with DAPI only and imaged with confocal 
microscopy. Scale bar, 50 μm. A. Normal intestine. B. Polyp. C–E. Tumors from 3 
EndoIRKO-Min mice and 3 controls were enzymatically digested and cells sorted by FACS 
using antibodies against EpCAM or CD31; status as double-negative or single-positive for 
this antigens is indicated below graphs. mRNA expression was measured by real-time PCR 
and normalized to expression of Rplp0, a ribosomal RNA. C. Enrichment of epithelial cells 
in EpCAM+ CD31− fraction shown by expression of Epcam mRNA. D. Enrichment of 
endothelial cells EpCAM− CD31+ fraction shown by expression of Kdr mRNA. Please note 
log scale. E. Expression of Insr mRNA. F. Tumor cells from Cdh5-cre Insrlox/lox ApcMin/+ 
mice (EndoIRKO-Min, “E”) or their littermate Insrlox/lox ApcMin/+ controls (“c”) were 
grown in a mixed culture and endothelial cells isolated by magnetic selection using ICAM-2 
conjugated Dynabeads at the first and second passage. ICAM-2-negative cells were collected 
at the first of these immuno-magnetic sortings while tumor endothelial cells were used after 
passage 3. Bone marrow, peripheral blood leukocytes and spleen were isolated and lysed. 
Representative Western blots of lysate is shown. G. Quantitation based on densitometry of 
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Western blots using material from 3 pairs of animals. H. Isolated tumor endothelial cells 
were serum-starved overnight, then treated with 10 nM insulin for 5 minutes. Representative 
Western blots are shown. I–J. Quantitation based on lysate from 4 independent experiments. 
K. glucose tolerance test. Plasma glucose concentrations were measured after intraperitoneal 
injection of 2 mg/g glucose in 5 EndoIRKO-Min mice and 5 control animals. L. Insulin 
tolerance test. Plasma glucose concentrations after intraperitoneal injection of 0.75 mU/g 
Humulin R in 5 EndoIRKO-Min mice and 5 control animals. All panels: *, p<0.05.
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Figure 4. Loss of the vascular endothelial cell insulin receptor enhances tumor formation
EndoIRKO-Min mice (“E”) and their littermate controls (“c”) were fed a regular chow diet 
and sacrificed at 16 weeks of age. A. The entire small intestine from two littermates. 
Adenomas are clearly visible as pale, circular lesions. B. Total number of tumors in the 
small intestine from EndoIRKO-Min mice (n=12) and controls (n=13). *, p=0.002. C. Total 
tumor area. *, p=0.02. D. Distribution of tumor number by diameter. E. Representative 
microphotos of CD31 immunohistochemistry in small intestinal tumors. Scale bar, 100 μm. 
F. Quantitation of tumor vascular density based on CD31 immunohistochemistry.
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Figure 5. VCAM-1 expression and leukocyte recruitment associated with insulin resistant tumor 
endothelium
Primary tumor endothelial cells were isolated by immuno-magnetic selection from a mixed 
culture of tumor cells. Cultures were used at passage 3 or 4. After overnight serum 
starvation, cells were treated with 10 nM insulin for 24 hours and in some experiments with 
or without 1 ng/ml TNF-α. A. Representative Western blot from tumor endothelial cells 
cultured from EndoIRKO-Min or control mice. B. Quantitative analysis based on 
densitometry from 3 independent experiments. C. Representative Western blot from tumor 
endothelial cells cultured from control animals with intact insulin receptors. D. Quantitative 
analysis based on densitometry from 3 independent experiments. E. Representative image 
frames from video of intravital microscopy of mesenteric venules. Leukocytes were labeled 
by intravenous injection of rhodamine 6G. Arrows point to rolling leukocytes. Scalebar, 100 
Wang et al. Page 21
Oncogene. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
μm. F. Quantitation of leukocyte rolling in 3 EndoIRKO mice and 4 controls. G. Results 
from a representative experiment using flow cytometry of enzymatically dissociated tumor 
cells. H. Quantitation of the frequency of neutrophils (Ly-6G+ cells) in 6 tumors per 
genotype, analyzed by flow cytometry. I. Quantitation of the frequency of macrophages 
(F4/80+ cells) in 6 tumors per genotype. All panels: *, p<0.05.
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